Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) Debt to Equity (2020 - 2023)

Silo Pharma (SILO) has disclosed Debt to Equity for 4 consecutive years, with $0.07 as the latest value for Q1 2023.

  • Quarterly Debt to Equity rose 816.9% to $0.07 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $0.07 through Mar 2023, up 816.9% year-over-year, with the annual reading at $0.04 for FY2022, 23.63% down from the prior year.
  • Debt to Equity hit $0.07 in Q1 2023 for Silo Pharma, up from $0.04 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.07 in Q1 2023 to a low of $0.0 in Q1 2021.
  • Historically, Debt to Equity has averaged $0.02 across 4 years, with a median of $0.01 in 2021.
  • Biggest five-year swings in Debt to Equity: soared 1291.04% in 2021 and later tumbled 80.47% in 2022.
  • Year by year, Debt to Equity stood at $0.0 in 2020, then skyrocketed by 1291.04% to $0.05 in 2021, then decreased by 23.63% to $0.04 in 2022, then skyrocketed by 98.51% to $0.07 in 2023.
  • Business Quant data shows Debt to Equity for SILO at $0.07 in Q1 2023, $0.04 in Q4 2022, and $0.0 in Q3 2022.